Portfolio News

TetraGenetics and ModiQuest Collaborating for the Discovery of Therapeutic Antibodies Against KCa3.1

TetraGenetics, a biopharmaceutical company developing novel therapeutics for autoimmune diseases, today announced a collaboration with ModiQuest Research, a Dutch biotechnology company with a suite of technologies for the discovery and optimization of monoclonal antibodies including those directed against difficult target antigens with low immunogenicity. Read more >>

Myomo, Inc. Announces Full Exercise of Underwriter’s Over-Allotment Option in Follow-On Public Offering

Myomo, Inc. (NYSE American: MYO), a commercial stage medical robotics company, today announced that Roth Capital Partners, the underwriter of Myomo’s follow-on offering, exercised in full its option to purchase 626,250 shares of common stock and accompanying warrants to purchase 626,250 shares of common stock, at a combined price to the public of $2.40 per share of common stock and accompanying warrant, for gross proceeds of approximately $1.5 million. Read more >>

With community’s help, legally blind Springfield teen now can see world through new electronic glasses

Reilly Gault, 15, has been legally blind for the majority of his life.
But on Friday evening, that all changed — Gault now can see.
Gault, 15, recently asked the community for some help to raise $10,000 so he could purchase computerized glasses that allow him to see the world through a new and clearer lens. The community responded with a resounding “yes” and donated more than enough to cover the cost of the electronic glasses, made by Canadian-based company eSight. […]

Just the Facts on Myomo, Inc. (MYO)

Myomo, Inc. (MYO) is an interesting player in the Healthcare space, with a focus on Medical Appliances & Equipment. The stock has been active on the tape, currently trading at $2.21, down from yesterday’s close by -24.04%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data. Read more >>

Myomo, Inc. Announces Pricing of Public Offering

Myomo, Inc. (NYSE American: MYO), a commercial stage medical robotics company, today announced that it has priced an underwritten public offering of 4,175,000 shares of its common stock and accompanying warrants to purchase 4,175,000 shares of common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock, at a combined price to the public of $2.40 per share of common stock and accompanying warrant, for gross proceeds of approximately […]

Myomo Expands MyoPro® Centers of Excellence Program

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced the addition of six new orthotics and prosthetics (O&P) locations to its Center of Excellence (CoE) program, which recognizes top O&P practices that support the MyoPro line of powered orthoses. MyoPro is currently the only lightweight wearable device that can help restore function in the paralyzed or weakened arms and hands of individuals who have suffered a stroke, brachial plexus injury (BPI) […]

Myomo, Inc. to Present at the 10th Annual LD Micro Main Event

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will be presenting at the 10th annual LD Micro Main Event on Tuesday, December 5th at 9:30 AM PST / 12:30 PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Chairman and Chief Executive Officer Paul R. Gudonis will be presenting, as well as meeting with investors. Read more >>